STEREOTACTIC RADIOTHERAPY PLUS AMIFOSTINE IN PATIENTS WITH LOW-GRADE PROSTATE CANCER

2.50
Hdl Handle:
http://hdl.handle.net/10755/165073
Category:
Abstract
Type:
Presentation
Title:
STEREOTACTIC RADIOTHERAPY PLUS AMIFOSTINE IN PATIENTS WITH LOW-GRADE PROSTATE CANCER
Author(s):
Montchal, Elaine; Katz, Alan J.; Witten, Matthew
Author Details:
Elaine Montchal, RN, Cyberknife Nurse Coordinator, Winthrop Hospital, Mineola, New York, USA, email: emontchal@winthrop.org; Alan J. Katz, MD; Matthew Witten, PhD
Abstract:
Radiation therapy (RT) for localized prostate cancer is associated with bowel toxicities that adversely affect long-term quality of life (QOL). Robotic stereotactic radiotherapy (Cyberknife) uses x-ray imaging to enable real-time corrections based on organ position. Although this technique reduces radiation exposure of normal tissues, protecting the anterior rectal wall remains difficult. Amifostine is a radioprotectant that has been shown to reduce toxicity to rectal tissues when administered to patients receiving RT for localized prostate cancer. We investigated the efficacy of intrarectal amifostine administered before RT for reduction of symptoms of bowel/rectal toxicity in patients receiving Cyberknife as primary or boost RT for localized prostate cancer. Amifostine (1500 mg/40 cc normal saline) was administered 20 minutes before each session. In patients receiving Cyberknife as primary RT, 35 Gy (7 Gy x 5 fractions within 7 days) was administered. Patients receiving boost RT had previously undergone external beam radiation (45 Gy; 1.8 Gy x 25 fractions), then received RT (18 Gy; 6 Gy x 3 fractions over consecutive days). Patients completed the bowel subscale of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire 1 to 3 weeks before treatment initiation, at treatment completion, and 3 months posttreatment. Maximum possible EPIC score is 100; higher scores indicate fewer symptoms and better QOL. Of 41 patients completing RT, 3-month follow-up data are available for 4 patients in the primary RT group (n=22; mean age, 68.1 y) and 3 in the boost RT group (n=19; mean age, 69.4 y). All primary patients had a baseline EPIC score of 100; mean baseline score for the boost group was 57 (range, 41 - 73.2). Posttreatment EPIC scores showed reduced bowel function for primary patients (mean, 62; range 19.6 - 87.5), and slight improvement for the boost patients (mean, 64.6; range, 42.8 - 82.1). At 3-month follow-up, mean scores increased in both groups (primary: 87.5, range, 80.4 - 92.8; boost: 96.4, range, 94.6 - 98.2), indicating recovery of bowel function to near-normal levels. Although intrarectal administration of amifostine is investigational, these results support further study of Cyberknife with amifostine pretreatment in the management of localized prostate cancer.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2007
Conference Name:
32nd Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
Las Vegas, Nevada, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titleSTEREOTACTIC RADIOTHERAPY PLUS AMIFOSTINE IN PATIENTS WITH LOW-GRADE PROSTATE CANCERen_GB
dc.contributor.authorMontchal, Elaineen_US
dc.contributor.authorKatz, Alan J.en_US
dc.contributor.authorWitten, Matthewen_US
dc.author.detailsElaine Montchal, RN, Cyberknife Nurse Coordinator, Winthrop Hospital, Mineola, New York, USA, email: emontchal@winthrop.org; Alan J. Katz, MD; Matthew Witten, PhDen_US
dc.identifier.urihttp://hdl.handle.net/10755/165073-
dc.description.abstractRadiation therapy (RT) for localized prostate cancer is associated with bowel toxicities that adversely affect long-term quality of life (QOL). Robotic stereotactic radiotherapy (Cyberknife) uses x-ray imaging to enable real-time corrections based on organ position. Although this technique reduces radiation exposure of normal tissues, protecting the anterior rectal wall remains difficult. Amifostine is a radioprotectant that has been shown to reduce toxicity to rectal tissues when administered to patients receiving RT for localized prostate cancer. We investigated the efficacy of intrarectal amifostine administered before RT for reduction of symptoms of bowel/rectal toxicity in patients receiving Cyberknife as primary or boost RT for localized prostate cancer. Amifostine (1500 mg/40 cc normal saline) was administered 20 minutes before each session. In patients receiving Cyberknife as primary RT, 35 Gy (7 Gy x 5 fractions within 7 days) was administered. Patients receiving boost RT had previously undergone external beam radiation (45 Gy; 1.8 Gy x 25 fractions), then received RT (18 Gy; 6 Gy x 3 fractions over consecutive days). Patients completed the bowel subscale of the Expanded Prostate Cancer Index Composite (EPIC) questionnaire 1 to 3 weeks before treatment initiation, at treatment completion, and 3 months posttreatment. Maximum possible EPIC score is 100; higher scores indicate fewer symptoms and better QOL. Of 41 patients completing RT, 3-month follow-up data are available for 4 patients in the primary RT group (n=22; mean age, 68.1 y) and 3 in the boost RT group (n=19; mean age, 69.4 y). All primary patients had a baseline EPIC score of 100; mean baseline score for the boost group was 57 (range, 41 - 73.2). Posttreatment EPIC scores showed reduced bowel function for primary patients (mean, 62; range 19.6 - 87.5), and slight improvement for the boost patients (mean, 64.6; range, 42.8 - 82.1). At 3-month follow-up, mean scores increased in both groups (primary: 87.5, range, 80.4 - 92.8; boost: 96.4, range, 94.6 - 98.2), indicating recovery of bowel function to near-normal levels. Although intrarectal administration of amifostine is investigational, these results support further study of Cyberknife with amifostine pretreatment in the management of localized prostate cancer.en_GB
dc.date.available2011-10-27T12:12:02Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:12:02Z-
dc.conference.date2007en_US
dc.conference.name32nd Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationLas Vegas, Nevada, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.